Stock Price, News, Quote and Profile of CUREVAC NV(NASDAQ:CVAC) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CUREVAC NV

NASDAQ:CVAC (5/3/2024, 7:00:01 PM)

After market: 3.15 +0.02 (+0.64%)

3.13

+0.36 (+13%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap702.09M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 1,049 full-time employees. The company went IPO on 2020-08-14. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Company Info

CUREVAC NV

Friedrich-Miescher-Str. 15

Tuebingen BADEN-WUERTTEMBERG 72076

P: 49707198830

CEO: Franz-Werner Haas

Employees: 1049

Website: https://www.curevac.com/

CVAC News

5 months ago - Seeking AlphaCureVac stock plunges after German court rules against it in BioNTech patent challenge

CureVacs stock plunges as German court invalidates patent, boosting rival BioNTechs shares.

5 months ago - Seeking AlphaPfizer stock hits 52-week low on weak guidance (NYSE:PFE)

Pfizer (PFE) shares hit a new low and its peers including Moderna (MRNA) and Novavax (NVAX) slipped as its 2024 outlook disappointed investors. Read more here.